ライフサイエンスコーパス: cell coat

1 rom the presence of a vascular smooth muscle cell coat.

2 erular capillary development, arterial mural cell coating, and lymphatic vessel development, required

3 l approximately 2.5 mm away from endothelial cell-coated beads within the matrix.

4 2 (P2), outer hair cell bundles have a dense cell coat, but have lost many of the lateral links seen

5 -1 RNA loads correlated with complete CD4+ T cell coating by TNX-355.

6 says, in subcutaneous xenograft models the T cells, coated by CV1-Fc, were depleted.

7 Here, we demonstrate that a single-cell coating composed of tannic acids and ferric ions, r

8 encodes rhabduscin's aglycone, and bacterial cell-coated immunosuppressants could be a general strate

9 Willebrand factor released from endothelial cells coated intravascular platelet aggregates.

10 r maturation, mediating formation of a mural cell coat investing infarct neovessels and protecting fr

11 thered aggrecan drops significantly when the cell coat is enriched with bottlebrush proteoglycans.

12 We suggest that this "bacterial cell coating" is necessary for the bacteriostatic functi

13 The cell-coat material is partially sensitive to subtilisin

14 We found placement of mesenchymal stem cell-coated matrix fistula plugs in 12 patients with chr

15 fore, this work has demonstrated a promising cell coating method for the display of aptamers for enha

16 our study, we developed an in vitro model of cell-coated microsized hydrogel spheres (MHSs) which all

17 Instead of lysing the bacterial cells, coating of APOL9a/b induces the production of out

18 ession induced upon stimulation with targets cells, coated or not with Abs.

19 On U373 cells, coated pits initiated on the dorsal membrane at t

20 d to infarct angiogenesis by forming a mural cell coat, stabilizing infarct neovessels.

21 ure scar, infarct neovessels acquire a mural cell coat that contributes to the stabilization of the m

22 cultured on human umbilical vein endothelial cell-coated transwells in the presence or absence of buc

23 1 and immobilized IgG or human breast cancer cells coated with a therapeutic mAb (trastuzumab) secret

24 ukin (IL)-2 or IL-12 and human breast cancer cells coated with an antitumor antibody (trastuzumab).

25 d in antiphospholipid syndrome, or red blood cells coated with anti-(alpha)-Rh(D) antibodies that med

26 Allogeneic cells coated with anti-CTLA-4 Ab induced immune hyporesp

27 HNE-induced apoptosis was compared in HLE-B3 cells coated with anti-RLIP76 IgG or preimmune IgG, by c

28 These cells efficiently lyse tumor cells coated with antibodies through concomitant crossli

29 endent cellular cytotoxicity against stromal cells coated with donor-specific antibodies in vitro.

30 eads that are specifically bound to cultured cells coated with extracellular matrix proteins or integ

31 Pre-coated cells coated with four bilayers of polymers were success

32 the intravascular survival of autologous red cells coated with human recombinant IgG antibody contain

33 Lastly, PMN lyse target cells coated with hyaluronic acid (HA), the principal li

34 thereby enhancing leukocyte killing of tumor cells coated with iC3b via naturally occurring antitumor

35 These data demonstrate that cells coated with mAb with enhanced affinity for CD16 ar

36 ponsive to LCMV NP 118-126 recognized target cells coated with NP 118-126 peptides derived from LCMV,

37 killer cells to kill HIV-1-infected CD4(+) T cells coated with RV144-induced IgG antibodies.

38 nize and eliminate uninfected primary CD4+ T cells coated with soluble gp120.

39 alveolar macrophage cell line and parasitic cells coated with SOWgp showed that the addition of anti

40 NK cells coated with the biomimetic bacterial capsule exhib

41 ls had increased activation against lymphoma cells coated with the clinically relevant anti-CD20 Abs

42 ct ex vivo cytotoxic activity against target cells coated with the epitope peptide, demonstrating tha

43 l killer (NK) cell-mediated killing of tumor cells coated with the Fc-optimized CD33 antibody DLE-HuM

44 molar levels of pE4R but did not lyse target cells coated with the self peptide at micromolar levels.

45 ed whether DCs phagocytosing killed lymphoma cells coated with tumor-specific antibody could elicit a

46 ice induced antiviral CTLs that lysed target cells coated with two of the three immunodominant epitop

47 The IgG4 isotype induced only cell coating without cell clearance or modulation.

48 report the development of biomimetic cancer cell coated zeolitic imidazolate frameworks (ZIFs) for t